Form 4: Director Charles Sigal Receives Equity Grant at Vir Biotech
Director Equity Grant
Director Charles Elliott Sigal was granted 8,000 restricted stock units and 16,000 stock options by Vir Biotechnology, Inc.
Summary
- Director Charles Elliott Sigal acquired 8,000 restricted stock units (RSUs) on May 27, 2026.
- The director was also granted 16,000 stock options with an exercise price of $9.10.
- Both the RSUs and the stock options are scheduled to vest in full on May 27, 2027.
- Following these transactions, the director holds 39,806 shares directly and maintains an indirect interest in 10,000 shares via Sigal Family Investments, LLC.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key leadership through standard vesting schedules.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Market volatility affecting the value of granted equity.
- Potential for future dilution if additional equity incentive plans are authorized.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of one-year cliff vesting for director equity is consistent with standard corporate governance practices in the U.S. biotech industry.
- The grant size is typical for non-executive director compensation packages at mid-cap biotechnology firms.
Related Party Transactions
- Reporting person maintains an indirect interest in 10,000 shares held by Sigal Family Investments, LLC.
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity grants on May 27, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Transaction date for RSU and stock option grants. |
| 05/27/2027 | Vesting date for both RSUs and stock options. |
| 05/26/2036 | Expiration date for the stock options. |
Keywords
Vir Biotechnology, VIR, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.